In this issue:
Risankizumab vs. ustekinumab for moderate-to-severe CD
IBD healthcare costs in Sweden
Speed of remission with advanced therapies for moderate-to-severe UC
CD-associated anorectal cancer: poor prognosis and high local recurrence
Treat-to-target monitoring colonoscopy after treatment initiation in IBD
Early ileocaecal resection for CD improves long-term outcomes over anti-TNF
Ustekinumab: promising option for treating postoperative CD recurrence
Early-life oral antibiotics increase paediatric-onset IBD risk
High processing of foods and IBD risk
Second-line biologics after anti-TNF failure
Please login below to download this issue (PDF)